Laserfiche WebLink
15 <br /> an accident for the period necessary to obtain assistance in responding to the accident or to <br /> obtain necessary emergency medical care. <br /> 5.3 Positive Test Results <br /> All positive test results shall be reviewed by a Medical Review Officer (MRO) who shall be a <br /> licensed physician with knowledge of substance abuse disorders. The MRO shall review and <br /> interpret confirmed positive urine test results from the laboratory and shall examine alternative <br /> medical explanations for such positive tests. Prior to the MRO's final decision to verify positive <br /> urine drug test results, the employee shall have the opportunity to discuss the results with the <br /> MRO. If the employee does not discuss the results of the positive urine drug test with the MRO <br /> within 72 hours after being contacted, or refuses the opportunity to do so, the MRO shall <br /> proceed with the positive verification. <br /> Section 6 Sample Collection <br /> The collection and testing of samples shall be performed only by a laboratory and by a <br /> physician or health care professional qualified and authorized to administer and determine the <br /> meaning of any test results. The laboratory performing the test shall be one that is certified by <br /> the National Institute of Drug Abuse (NIDA). <br /> Collection of blood or urine samples shall be conducted in a manner which provides for the <br /> highest, reasonable degree of security for the sample and freedom from adulteration. Blood or <br /> urine samples will be submitted as per NIDA standards including the recognized chain of <br /> custody procedures. Employees have the right for Union representation to be present. <br /> Employees shall not be witnessed while submitting a urine specimen. Prior to submitting to a <br /> urine or blood sample, the employee will be required to sign a consent and release form as <br /> attached to this Article. <br /> A split sample shall be reserved in all cases for an independent analysis in the event of a non- <br /> negative specimen. All samples must be stored in a scientifically acceptable preserved manner <br /> as established by NIDA. All positive confirmed samples and related paperwork must be retained <br /> by the laboratory for at least six (6) months or for the duration of any grievance, disciplinary <br /> action, or legal proceedings, whichever is longer. At the conclusion of this period, the <br /> laboratory's paperwork and specimen shall be destroyed. Tests shall be conducted in a manner <br /> to ensure that an employee's legal drug use and diet does not affect the test result. <br /> Section 7 Drug Testing <br /> The laboratory shall test for only the substances and within the limits as follows for the initial and <br /> confirmatory test as provided within NIDA standards. The initial test shall use an immunoassay <br /> test procedure, which meets the requirements of the Food and Drug Administration for <br /> commercial distribution. The following initial cutoff levels shall be used when screening <br /> specimens to determine whether they are negative for these five drugs or classes of drugs: <br /> INITIAL TESTING: <br /> Marijuana metabolites 100 ng/ml <br /> Cocaine metabolites 300 ng/ml <br /> Opiate metabolites' 300 ng/ml <br /> Phencyclidine <br /> 56 <br />